R&D entity Global Health Solutions, LLC, which focuses on novel, best in class products for infection control, skin, and wound care, is working towards developing a non-antibiotic solution for superficial skin infection.
Hexagen Wound Dressing, the company’s lead advanced wound care product, is a topical formula that is used nationwide to assist with healing in acute and chronic wounds. However, this product doesn’t address the needs of patients with infected wounds. To do so, the company is expanding its drug development programme to include a superficial infection treatment candidate that is based on the same technology that underlies Hexagen Wound Dressing.
“Standard of care, topical treatments for skin-based infection have seen little to no innovation in the past half-century. Yet, over this same period of time, we have seen a dramatic rise in the number of antimicrobial resistant organisms and resulting disease states,” said Global Health Solutions founder and CEO Bradley Burnam. “Our non-antibiotic new drug candidate is gentle, powerful, and has shown no signs of resistance among even the most virulent pathogens. We look forward to working closely with the FDA to bring this important product to fruition.”
CMO Dr Neil Ghodadra said that the growing number of antibiotic resistant organisms is alarming and presents daunting clinical implications: “Doctors need viable, alternative treatment options for acute and chronic superficial infections, especially those colonised by drug resistant microbes. This is an important product not just for physicians, but for patients who may become victims of pathogens for which we lack sufficient tools to address.”